Efficacy of l‐Arginine treatment in patients with HTLV‐1‐associated neurological disease

OBJECTIVE: HTLV‐1 infection causes HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), resulting in loss of motor function. In this Phase 2 trial, we assessed the efficacy and safety of l‐arginine in patients with HAM/TSP. METHODS: This open‐label, single‐arm, Phase 2 study enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Nozuma, Satoshi, Matsuura, Eiji, Tashiro, Yuichi, Nagata, Ryusei, Ando, Masahiro, Hiramatsu, Yu, Higuchi, Yujiro, Sakiyama, Yusuke, Hashiguchi, Akihiro, Michizono, Kumiko, Higashi, Keiko, Matsuzaki, Toshio, Kodama, Daisuke, Tanaka, Masakazu, Yamano, Yoshihisa, Moritoyo, Takashi, Kubota, Ryuji, Takashima, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930431/
https://www.ncbi.nlm.nih.gov/pubmed/36547017
http://dx.doi.org/10.1002/acn3.51715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930431/
https://www.ncbi.nlm.nih.gov/pubmed/36547017
http://dx.doi.org/10.1002/acn3.51715

Ejemplares similares